Ipsen: new positive data for Cabometyx
(CercleFinance.com) - Ipsen announces the first presentation of new positive analyzes of the pivotal phase III study CheckMate-9ER, evaluating the combination of its Cabometyx with Opdivo, versus sunitinib, in the first-line treatment of advanced kidney carcinoma.
Over a median follow-up period of two years, this association thus continues to demonstrate superior progression-free survival, overall survival and an objective response rate compared to sunitinib.
Patients treated with Cabometyx, in combination with Opdivo, saw a significant improvement in their quality of life compared to sunitinib in a separate review of CheckMate-9ER.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Over a median follow-up period of two years, this association thus continues to demonstrate superior progression-free survival, overall survival and an objective response rate compared to sunitinib.
Patients treated with Cabometyx, in combination with Opdivo, saw a significant improvement in their quality of life compared to sunitinib in a separate review of CheckMate-9ER.
Copyright (c) 2021 CercleFinance.com. All rights reserved.